According to the latest report by IMARC Group, titled “Hematologic Malignancies Market Size: Global Industry Trends, Size, Growth, Opportunity and Forecast 2021-2026”,the global hematologic malignancies market exhibited strong growth during 2015-2020 and expects the market to grow at a CAGR of around 10% during 2021-2026.
Hematologic malignancies refer tomedical conditions related to blood-producing cells, including lymphoma, multiple myeloma, leukemia, etc. The blood-producing cells comprise platelets for wound clotting, white blood cells (WBCs) for immune protection, and red blood cells (RBCs) to carry oxygen. Hematologic malignancies can be diagnosed using tests, such as cytogenetics, microscopy, polymerase chain reaction (PCR), flow cytometry, immunophenotyping, fluorescence in situ hybridization (FISH), gene expression profiling, etc. At present, several drugs, including histone deacetylase inhibitors, antitumor antibiotics, Janus kinase (JAK) inhibitors, etc., are available for treatment based on diagnostic tests.
As the novel coronavirus (COVID-19) crisis takes over the world, we are continuously tracking the changes in the markets, as well as the industry behaviours of the consumers globally and our estimates about the latest market trends and forecasts are being done after considering the impact of this pandemic.
Global Hematologic Malignancies Market Trends:
The rising incidences of acute myeloid leukemia (AML) are driving the hematologicmalignancies market. Furthermore, various advancements in immunohistochemistry (IHC) and accurate diagnosis of hematologic malignancies by exposing tissue samples to numerous antibodies, are fueling the market growth. Additionally, surgical therapy is available for tissue diagnosis and treatment of lymphoma complications, such as obstruction, perforation, stricture, etc. Moreover, multiple label expansions of premium-priced agents, including brexucabtagene autoleuce and CAR T-cell therapies, and the launch of several novel therapies are bolstering the product demand. Apart from this, ongoing research and development activities to introduce advanced drugs for patients with complex hematologic malignancies are expected to fuel the market in the coming years.
Request Free Sample Report: https://www.imarcgroup.com/hematologic-malignancies-market/requestsample
Global Hematologic Malignancies Market 2021-2026 Analysis and Segmentation:
The competitive landscape of the market has been studied in the report with the detailed profiles of the key players operating in the market.
AbbVie Inc., AstraZeneca plc, Bristol-Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche Ltd, GlaxoSmithKline plc, Johnson & Johnson, Merck & Co. Inc, Novartis AG, Pfizer Inc., Sanofi S.A. and Takeda Pharmaceutical Company Limited.
The report has segmented the market on the based on region, type, therapy and end user.
Breakup by Type:
- Multiple Myeloma
Breakup by Therapy:
- Stem Cell Transplantation
Breakup by End User:
- Diagnostics Centers
- Research Centers
Breakup by Region:
- North America:( United States, Canada)
- Asia-Pacific: (China, Japan, India, South Korea, Australia, Indonesia, Others)
- Europe: (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
- Latin America: (Brazil, Mexico,Others)
- Middle East and Africa
Ask Analyst for Customization and Explore Full Report with TOC & List of Figure: https://www.imarcgroup.com/hematologic-malignancies-market
If you want latest primary and secondary data (2021-2026) with Cost Module, Business Strategy, Distribution Channel, etc. Click request free sample report, published report will be delivered to you in PDF format via email within 24 to 48 hours of receiving full payment.
Key highlights of the report:
- Market Performance (2015-2020)
- Market Outlook (2021- 2026)
- Porter’s Five Forces Analysis
- Market Drivers and Success Factors
- SWOT Analysis
- Value Chain
- Comprehensive Mapping of the Competitive Landscape
If you need specific information that is not currently within the scope of the report, we can provide it to you as a part of the customization.
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
Company Name: IMARC Group
Toll Free Number: USA: +1-631-791-1145 | Asia: +91-120-433-0800
Address: 30 N Gould St, Ste R
Sheridan, WY 82801, USA
Follow us on twitter: @imarcglobal